Human Papillomavirus Associated Cancer Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight

DelveInsight's, "Human Papillomavirus Associated Cancer Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human Papillomavirus Associated Cancer pipeline landscape. It covers the Human Papillomavirus Associated Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Human Papillomavirus Associated Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Human Papillomavirus Associated Cancer Pipeline? Click here to explore the therapies and trials making headlines @ Human Papillomavirus Associated Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Human Papillomavirus Associated Cancer Pipeline Report
• On 25 September 2025, New York University announced a clinical trial is identify an effective and implementable set of implementation strategies to increase cervical cancer prevention in Malawi.
• In July 2025, Marengo Therapeutics Inc. conducted a Phase 1/2 study consists of two parts: Phase 1 Dose Escalation and Phase 2 Dose Expansion. In Phase 1 Dose Escalation, STAR0602 will be administered intravenously in participants with advanced solid tumors to assess safety/tolerability profile of STAR0602 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of STAR0602.
• DelveInsight's Human Papillomavirus Associated Cancer Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Human Papillomavirus Associated Cancer treatment.
• The leading Human Papillomavirus Associated Cancer Companies such as Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.
• Promising Human Papillomavirus Associated Cancer Therapies such as V503, GARDASIL, ABI-2280, 2LPAPI®, V501, Cervarix, GSK580299, MEDI0457 and others.

Want to know which companies are leading innovation in Human Papillomavirus Associated Cancer? Dive into the full pipeline insights @ Human Papillomavirus Associated Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Human Papillomavirus Associated Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Human Papillomavirus Associated Cancer Pipeline Report also highlights the unmet needs with respect to the Human Papillomavirus Associated Cancer.

Human Papillomavirus Associated Cancer Overview
Human Papillomavirus infection is linked with several cancers such as cancer cervix, vagina, head and neck, anal, and carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers.

Human Papillomavirus Associated Cancer Emerging Drugs Profile
• STP909: Sirnaomics Inc
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.
• RTX-321: Rubius Therapeutics
RTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.
• BVAC-C: Cellid Co Ltd
BVAC-C uses HPV type 16/18's carcinogen gene, E6/E7's recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.
• GX-188E: Genexine Inc
GX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.
• ITI-2000: Immunomic Therapeutics Inc
ITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

If you're tracking ongoing Human Papillomavirus Associated Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Human Papillomavirus Associated Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Human Papillomavirus Associated Cancer Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Human Papillomavirus Associated Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Human Papillomavirus Associated Cancer Treatment.
• Human Papillomavirus Associated Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Human Papillomavirus Associated Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Human Papillomavirus Associated Cancer market.

Human Papillomavirus Associated Cancer Companies
Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.

Human Papillomavirus Associated Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous

Human Papillomavirus Associated Cancer Products have been categorized under various Molecule types such as,
• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy

From emerging drug candidates to competitive intelligence, the Human Papillomavirus Associated Cancer Pipeline Report covers it all - check it out now @ Human Papillomavirus Associated Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Human Papillomavirus Associated Cancer Pipeline Report
• Coverage- Global
• Human Papillomavirus Associated Cancer Companies- Turnstone Biologics, Advaxis, AstraZeneca, VLP The Vaccines Company SL, Voltron Therapeutics Inc, Rubius Therapeutics, Inovio Pharmaceuticals, Bristol-Myers Squibb, Precigen Inc, Privo Technologies, ViciniVax BV, Avalia Immunotherapies, BlueSky Immunotherapies, Cellid Co Ltd, Cue Biopharma, Cullinan Oncology, Genexine, EyeGene, Hookipa Pharma, Immunomic Therapeutics, ISA Pharmaceuticals BV, SQZ Biotechnologies and others.
• Human Papillomavirus Associated Cancer Therapies- V503, GARDASIL, ABI-2280, 2LPAPI®, V501, Cervarix, GSK580299, MEDI0457 and others.
• Human Papillomavirus Associated Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human Papillomavirus Associated Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Human Papillomavirus Associated Cancer Treatment landscape in this detailed analysis @ Human Papillomavirus Associated Cancer Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Human Papillomavirus Associated Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human Papillomavirus Associated Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac: Advaxis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. PRGN-2009: Precigen PII
12. Drug profiles in the detailed report.....
13. Mid Stage Products (Phase II)
14. HB-200: Hookipa Pharma Inc
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report.....
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report.....
22. Inactive Products
23. Human Papillomavirus Associated Cancer Key Companies
24. Human Papillomavirus Associated Cancer Key Products
25. Human Papillomavirus Associated Cancer - Unmet Needs
26. Human Papillomavirus Associated Cancer - Market Drivers and Barriers
27. Human Papillomavirus Associated Cancer - Future Perspectives and Conclusion
28. Human Papillomavirus Associated Cancer Analyst Views
29. Human Papillomavirus Associated Cancer Key Companies
30. Appendix

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.